Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells - Takeaway - MDSpire
Feature

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

Study reveals Fc fragment of antibody is essential for activating microglia to clear amyloid plaques

  • April 7, 2026

  • 3 min

Share

  • 1

    Lecanemab binds amyloid plaques and activates microglia.

  • 2

    The Fc fragment is crucial for therapeutic efficacy.

  • 3

    Microglial activation leads to plaque degradation without significant side effects.

  • 4

    Upregulated gene SPP1 promotes plaque clearance.

  • 5

    Immune engagement can have adverse effects that need further exploration.

  • 6

    Future therapy designs may focus on modulating immune response rather than just targeting amyloid.

Original Source(s)

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

  • April 7, 2026

Related Content

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

The Hidden Diversity of Amyloid Plaques

A multimodal MSI approach reveals how plaque-associated lipid signatures differ across brain regions in Alzheimer’s disease